Pfizer, Inc. (hereinafter Pfizer), a U.S.-based pharmaceutical company, states that it is committed to being an "exemplary corporate citizen" that is "dedicated to discovering and developing innovative medicines and making them available to people all around the world." Pfizer boasts about its philanthropic focus, yet, like any for-profit organization, Pfizer has a responsibility to its shareholders to be profitable. Pfizer must balance its obligations to its shareholders with its stated philanthropic vision, while also being mindful of the public relations ramifications of its decisions. This article presents a business case developed to encourage business students to consider the legal and ethical ramifications of Pfizer's handling of three drugs in the international context. Part I of this article consists of a case study involving actual issues confronting Pfizer. The case is structured around key events regarding the use of three of Pfizer's pharmaceutical products which involve different legal and ethical considerations. The assignment at the end of the case is designed to prompt students to identify legal and ethical issues confronting the company, analyze the issues, and then propose solutions for Pfizer. Part II of this article is a teaching note, which includes learning objectives, potential uses of the case, a discussion about each of the assigned case questions, and suggestions regarding evaluation of the assignment. (Contains 115 footnotes.)